Stifel Nicolaus Has Lowered Expectations for Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price

Bolt Biotherapeutics (NASDAQ:BOLT) had its target price cut by analysts at Stifel Nicolaus from $1.50 to $1.25 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 185.65% from the company’s current price.

Bolt Biotherapeutics Price Performance

Shares of NASDAQ BOLT opened at $0.44 on Tuesday. The stock has a market cap of $16.75 million, a P/E ratio of -0.26 and a beta of 0.94. The firm’s 50-day simple moving average is $0.47 and its 200 day simple moving average is $0.56. Bolt Biotherapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.56. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.38) EPS for the quarter, hitting analysts’ consensus estimates of ($0.38). The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. Equities analysts expect that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Hedge funds have recently modified their holdings of the company. FMR LLC boosted its stake in Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after buying an additional 28,773 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Bolt Biotherapeutics in the 4th quarter worth approximately $42,000. Velan Capital Investment Management LP acquired a new position in shares of Bolt Biotherapeutics in the 4th quarter worth approximately $27,000. Squarepoint Ops LLC bought a new stake in shares of Bolt Biotherapeutics in the 4th quarter worth approximately $26,000. Finally, Millennium Management LLC acquired a new stake in Bolt Biotherapeutics during the fourth quarter valued at approximately $25,000. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.